Table 3 Baseline demographic and clinical characteristics (overall and by previous treatment)
Treatment in previous study | |||
|---|---|---|---|
Variable | OROS®hydromorphone (n = 35) | CR morphine (n = 33) | Overall (n = 68) |
Mean (SD) age, years | 57.4 (15.24) | 58.3 (10.05) | 57.8 (12.89) |
Sex, n (%) | |||
Male | 9 (25.7) | 16 (48.5) | 25 (36.8) |
Female | 26 (74.3) | 17 (51.5) | 43 (63.2) |
Race, n (%) | |||
White | 35 (100.0) | 32 (97.0) | 67 (98.5) |
Asian | 0 | 1 (3.0) | 1 (1.5) |
Mean (SD) height, cm | 165.9 (8.32) | 168.2 (10.76) | 167.0 (9.58) |
Mean (SD) weight, kg | 62.4 (16.09) | 68.0 (9.90) | 65.1 (13.60) |
Mean (SD) BMI, kg/m2 | 22.8 (5.90) | 24.2 (4.18) | 23.5 (5.14) |
Cancer type, n (%) | |||
Breast | 11 (31.4) | 12 (36.4) | 23 (33.8) |
Gastrointestinal | 9 (25.7) | 5 (15.2) | 14 (20.6) |
Genitourinary | 5 (14.3) | 3 (9.1) | 8 (11.8) |
Lung | 5 (14.3) | 7 (21.2) | 12 (17.6) |
Oral cavity | 1 (2.9) | 1 (3.0) | 2 (2.9) |
Other | 4 (11.4) | 5 (15.2) | 9 (13.2) |
Location of metastases, n (%)1 | 57 (100) | 58 (100) | 115 (100) |
Bone | 16 (28.1) | 20 (34.5) | 36 (31.3) |
Bone marrow | 1 (1.8) | 1 (1.7) | 2 (1.7) |
Brain | 1 (1.8) | 2 (3.4) | 3 (2.6) |
Kidney | 1 (1.8) | 0 | 1 (0.9) |
Liver | 9 (15.8) | 9 (15.5) | 18 (15.7) |
Lung | 6 (10.5) | 6 (10.3) | 12 (10.4) |
Lymph node | 8 (14.0) | 6 (10.3) | 14 (12.2) |
None | 4 (7.0) | 7 (12.1) | 11 (9.6) |
Other | 11 (19.3) | 7 (12.1) | 18 (15.7) |
Predominant pain type, n (%) | |||
Bone or soft tissue | 22 (62.9) | 26 (78.8) | 48 (70.6) |
Mixed | 6 (17.1) | 3 (9.1) | 9 (13.2) |
Visceral | 7 (20.0) | 4 (12.1) | 11 (16.2) |